An observational study in Pain and Fybromyalgia, sponsored by Zülal TATAR. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Zülal TATAR · Observational
Among 1,712 studies in Pain with a site in Turkey — 322 open to participants now, 372 under way, none of them phase 3. Pain · Turkey.
Among the 1,712 studies in Pain with a site in Turkey, this one is the 129th largest by planned enrollment of the 223 observational ones that give a count, is one of 180 that started in 2026, is one of 223 observational ones, reaches primary completion later than 339 of the 371 other live ones, and was the 1,604th registered.
10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →322 of the 1,712 studies in Pain with a site in Turkey are open now. Recruiting first, the newest first:
Mersin University · Sites in Turkey
Ages 18+
Artvin Coruh University · Sites in Turkey
Ages 6–12
Mersin University · Sites in Turkey
Ages 18+
Bahçeşehir University · Sites in Turkey
Ages 45–65
Istanbul University · Sites in Turkey
Ages 1–12
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,712 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 6 · Phase 4 34
First in 2006; this study’s year is marked. 180 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 100 across 1,252 observational studies indexed under Pain.
Median enrollment 70 across the 1,489 interventional studies, 84 across the 223 observational. Of the 1,268 that completed or were terminated, 7 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 1,712 have an industry lead sponsor. The 10 most frequent:
Zülal TATAR is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Zülal TATAR has 2 studies filed under Pain — fewer than ten, so there is no comparison to draw.
84 of the studies in Pain with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07707726Ankara City Hospital BilkentVirtual Reality in Ingrown Toenail Surgery | 2026-11-15 |
| NCT07846098Cumhuriyet UniversityComparison of Intraosseous Anesthesia and Inferior Alveolar Nerve Block for Primary Mandibular Molars | 2026-11-20 |
| NCT07404163Tarsus UniversityWalkway Used in Postoperative Mobilization | 2026-11-30 |
| NCT07915804Istanbul UniversityPerfusion Index for Postoperative Pain Assessment in Pediatric Adenotonsillectomy | 2026-11-30 |
| NCT07892196Antalya Training and Research HospitalDoes Chronic Pain Change Over Time in Children With Duchenne Muscular Dystrophy? | 2026-11-30 |
Among the 1,712 studies in Pain with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess pain in individuals with fibromyalgia using abstract animations and graphical body maps, and to investigate the determinants of pain quality.
The study will be conducted on individuals followed by the Rheumatology Department of Pamukkale University Faculty of Medicine and diagnosed with Fibromyalgia according to the 2016 ACR Fibromyalgia Syndrome diagnostic criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Painimation Mobile App
An electronic pain assessment tool designed to measure the location, nature, and intensity of pain using "pain animations and graphical images." Patients use a colorable body image to indicate the areas affected by pain. They then select from eight animations that represent their pain experiences. The size, speed, and intensity of these animations can be adjusted to accurately represent pain severity. Painimation animations are derived from the McGill Pain Questionnaire Short Form. They were developed through a human-centered design process involving patients with acute and chronic pain, clinicians, researchers, and design students. The animations correspond to the following pain qualities: "pounding," "shooting," "throbbing," "tingling," "cramping," "burning," "stabbing," and "electrifying." The area of the body affected by pain will be calculated based on the proportion of selected pixels.
Time frame: At baseline (Day 1)
PainDetect Questionnaire
The PainDetect Questionnaire is a simple, self-administered, and convenient screening questionnaire that allows for the identification of neuropathic pain components in patients with chronic pain. It consists of four main sections. The total score is calculated by summing the scores from the last three sections and ranges from -1 to 38. Scores of 12 and below indicate that the neuropathic pain component is unlikely, while scores of 19 and above indicate a high probability of the neuropathic pain component being present. Scores between 12 and 19 are considered inconclusive.
Time frame: At baseline (Day 1)
Central Sensitization Scale
The Central Sensitization Scale consists of two sections. Section A comprises 25 items that assess symptoms related to physical and emotional health commonly seen in disorders associated with central sensitization. Each item is scored on a 5-point Likert scale ranging from (0) "never" to (4) "always," with a total score of 100. Higher scores indicate a higher level of symptom presence. Section B includes 7 diagnoses assessed within the scope of central sensitization syndrome (tension-type headache or migraine, fibromyalgia, irritable bowel syndrome, restless legs syndrome, temporomandibular joint disorder, chronic fatigue syndrome, and multiple chemical sensitivities) and three additional diagnoses reported to be associated with central sensitization (depression, anxiety or panic attacks, and neck injury). Participants are asked the following question: "Have you been diagnosed by a doctor with any of the following conditions?" and the year of diagnosis is indicated.
Time frame: At baseline (Day 1)
Pain Catastrophizing Scale
The Pain Catastrophizing Scale is a scale used to assess the psychological aspects of pain-related symptoms in three dimensions: rumination, helplessness, and amplification. The scale includes 13 items related to specific emotions and thoughts defined as negative associations. Five of these items relate to rumination, six to helplessness, and two to amplification. Patients are asked how frequently they recall each thought in these items. Each item is scored between 0-4, and the total score is calculated between 0-52.
Time frame: At baseline (Day 1)
Brief Pain Inventory
The Brief Pain Inventory is a short, easy-to-administer assessment method that can be used to evaluate pain. It consists of two sections: pain intensity and impairment caused by pain. It has 4 items related to pain intensity and 7 items related to impairment caused by pain. Each item is rated on a scale of 0 to 10. The total score for both sections is calculated by summing the scores given to each item and dividing the sum by the number of questions, and ranges from 0 to 10. Higher scores indicate more pain and greater impairment caused by pain.
Time frame: At baseline (Day 1)
Fatigue Severity Scale
Published by Krupp in 1989, the FSS consists of nine items. For each item, the patient is asked to choose a number between 1 and 7 indicating how much they agree with the statement; 1 means strongly disagree, and 7 means strongly agree. Generally, scores of 4 and above indicate severe fatigue.
Time frame: At baseline (Day 1)
The Short Form-12 Health Questionnaire
A summary version of the Short Form-36 Health Questionnaire, the SF-12 can also be divided into physical and mental sections and consists of a total of 12 questions. The physical component of the scale is scored between 24 and 56 points, while the mental component is scored between 19 and 60 points. Higher scores on the scale indicate a higher quality of life.
Time frame: At baseline (Day 1)
Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale is a 14-item, two-factor scale that assesses patients' anxiety and depression levels. Seven of these items assess anxiety, and the other seven assess depression. Each item is scored on a four-point scale. The total score for anxiety and depression ranges from 0 to 21. Scores between 0 and 7 indicate a normal emotional state. Scores above 7 on either the anxiety or depression subscales have been reported to indicate the presence of anxiety and depressive disorders.
Time frame: At baseline (Day 1)
Revised Fibromyalgia Impact Questionnaire
The Revised Fibromyalgia Impact Questionnaire is a questionnaire evaluating limitations and functional disability in patients with fibromyalgia. It consists of 21 questions divided into three sections: function, general, and symptoms. All questions are rated on a numerical scale from 0 to 10. A score of 70 or higher indicates severe disability in this patient group. Higher scores indicate greater fibromyalgia-related disability.
Time frame: At baseline (Day 1)
Started Feb 2026 (actual). Primary completion is estimated for Apr 2027, 14 months after the start.
Of 504 non-industry observational studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 14 months is below that.
Counting every sponsor, half of 519 studies reached it within 18 months; a quarter within 8 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zülal TATAR